文献速递肾小球疾病肾移植

狼疮肾炎临床缓解期无症状血清学再激活的抢先免疫抑制治疗:多中心随机对照试验

A prospective multicenter randomized controlled trial pre-emptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission.
PubMed 文献 · Kidney Int · 2026-03-27

抢先治疗组24个月无肾脏 flare 生存率为100%,对照组为80%,差异显著;治疗耐受性良好。

要点

  • 抢先治疗可显著降低24个月肾脏 flare 风险。
  • 抢先治疗组抗dsDNA抗体和C3较基线改善,对照组无改善。
  • 不良事件少且两组相似,肾功能保持稳定。

核心结论

  • 抢先适度增加免疫抑制可有效预防狼疮肾炎临床缓解期无症状血清学再激活患者的肾脏 flare,且耐受性良好。

主要发现

  • 抢先治疗组无肾脏 flare 发生,对照组发生5例肾脏 flare,中位时间6.0个月(IQR 3.0-10.0)。
  • 抢先治疗组24个月无肾脏、无肾外及无总体 flare 生存率均优于对照组(100% vs. 80%,91% vs. 72%,91% vs. 52%,均显著)。
  • 抢先治疗组抗dsDNA抗体和C3较基线改善,对照组无改善;两组不良事件少且相似,肾功能稳定。

关键数值与推荐

  • 抢先治疗方案:泼尼松龙从≤5 mg/d增至0.4-0.5 mg/kg/d,吗替麦考酚酯增至1.5 g/d或硫唑嘌呤增至100 mg/d,12周内泼尼松龙减回原剂量。
  • 主要终点为24个月无肾脏 flare 生存率;随访24个月。

临床怎么用

  • 对于狼疮肾炎临床缓解期出现无症状血清学再激活且维持低剂量激素联合吗替麦考酚酯或硫唑嘌呤的患者,可考虑抢先适度增加免疫抑制以预防肾脏 flare。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The management of patients with lupus nephritis (LN) in clinical remission who demonstrate asymptomatic serological reactivation remains uncertain. Results from our previous study suggested that a pre-emptive moderate increase of immunosuppressive treatment might reduce disease flares. METHODS: Here, we conducted a prospective multicenter randomized controlled trial to compare pre-emptive treatment (PT) against observant management (Control) in clinically stable patients with LN and asymptomatic serological reactivation who were receiving low-dose glucocorticoid and mycophenolate or azathioprine as maintenance immunosuppression. PT included an increase in prednisolone dose from ≤5 mg/d to 0.4-0.5 mg/kg/d and an increase in mycophenolate or azathioprine dose to 1.5 g/d and 100 mg/d, respectively, followed by tapering of prednisolone dose to the original level by 12 weeks. Patients were followed for 24 months from randomization. The primary outcome was 24-month survival free of kidney flares. Secondary outcomes included survival free of extra-kidney flares, change in kidney and immunological parameters, and adverse events. RESULTS: Forty-nine patients were randomized (24 PT and 25 Control). No kidney flare occurred in PT while five kidney flares occurred at 6.0 (interquartile range: 3.0-10.0) months in Controls. PT patients had superior 24-month survival free of kidney, extra-kidney, and overall flares than Controls (100% vs. 80%, 91% vs. 72%, and 91% vs. 52%, respectively, significant for all). PT patients showed improved anti-dsDNA and C3 compared to baseline, but not patients in the Control arm. Adverse events were few and similar, and kidney function remained stable in both groups. CONCLUSIONS: A pre-emptive moderate increase of immunosuppression was effective in preventing kidney flares in patients with LN and with asymptomatic serological reactivation and was well tolerated. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04870359.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Yap DYH, Chan SCW, Wong PYH, et al. A prospective multicenter randomized controlled trial pre-emptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission. Kidney Int. 2026. PMID: 41905595. doi:10.1016/j.kint.2026.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。